ArticleIntractable & rare diseases research2013
Leiomyosarcoma: Principles of management.
Article in Intractable & rare diseases research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Web-based nomograms for predicting overall survival and cancer-specific survival in retroperitoneal leiomyosarcoma: a population-based analysis.Journal of cancer research and clinical oncology · 2023Trial
- Molecular carcinogenesis and genetic insights in leiomyosarcoma: involvement of PI3K/AKT/mTOR/MAPK/ERK pathway.American journal of cancer research · 2026Review
- Primary cutaneous leiomyosarcoma: demographics and survival benefit of surgical management in a US population.Proceedings (Baylor University. Medical Center) · 2025Article
- Endoscopic endonasal approach for resection of sellar leiomyosarcoma metastasis: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Leiomyogenic Tumor of the Spine: A Systematic Review.Cancers · 2024Review
- Article
- Article
- Totally laparoscopic resection using delta-shaped anastomosis of jejunal leiomyosarcoma with intussusception at the angle of Treitz: a case report.Surgical case reports · 2022Article
- Retrospective immunohistochemical investigation of suspected non-visceral leiomyosarcoma in dogs.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2022Article
- What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?Current treatment options in oncology · 2022Review
- Great saphenous vein leiomyosarcoma: A case report.Annals of medicine and surgery (2012) · 2022Article
- Magnetic resonance imaging of soft tissue sarcoma: features related to prognosis.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2021Review
- Primary cutaneous Leiomyosarcoma on the left iliac region: A rare case report from Syria.Annals of medicine and surgery (2012) · 2021Article
- Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?Current treatment options in oncology · 2021Review
- Review
- Kissing tumors; the concurrent diagnosis of leiomyosarcoma and squamous cell carcinoma of the esophagus.BMC surgery · 2021Article
- Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas.Frontiers in oncology · 2021Article
- Leiomyosarcoma of the Inferior Vena Cava with Hepatic and Pulmonary Metastases: Case Report.Journal of radiology case reports · 2019Article
- Ileal leiomyosarcoma presenting with intussusception.Journal of surgical case reports · 2019Article
- Soft tissue leiomyosarcoma-diagnostics, management, and prognosis: Data of the registry cancer of the center of Tunisia.Rare tumors · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term soft-tissue sarcomas (STS) embraces more than 50 different sub-types that are often associated with poor prognosis. Only a very limited number of agents are active against STS. Doxorubicin and ifosfamide are widely accepted as the most effective compounds. However, their low response rates and poor impact on the overall survival of the patients illustrate the need for new treatment options. Among them, leiomyosarcomas are one of the most frequently occurring subtypes. In spite of the relatively high incidence of leiomyosarcomas, the overall effectiveness of the currently available systemic treatments is still poor. The heterogeneity of its biological origin, clinical behavior and responsiveness to chemotherapy, together with the scarcity of successful clinical trials, makes the treatment of leiomyosarcoma especially challenging. In addition, the evidence-based treatment for leiomyosarcoma comes from trials in which, in the majority of cases, no distinctions have been made among the different STS sub-types. As a result, every therapeutic decision should be made on an individual basis in collaboration with the patient. The results of new specific histology-designed clinical trials should aid decision making in this complex field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.